Literature DB >> 3306904

Loperamide treatment of the irritable bowel syndrome.

N Hovdenak.   

Abstract

The effect of loperamide was investigated in a double-blind, placebo-controlled study in 60 patients with irritable bowel syndrome (IBS). Active treatment was given in low dosage (4 mg nocte). The effect of treatment was assessed in clinical subgroups. In a group of patients with painless diarrhoea (n = 16) there was a highly significant improvement in stool frequency and consistency. In a group with alternating bowel habits and abdominal pain (n = 21) there was also a statistically significant improvement in stool frequency and consistency as well as significantly fewer painful days during loperamide treatment. Patients with alternating bowel habits and no pain (n = 12) experienced no symptomatic improvement, and patients with constipation (n = 9) generally felt worse on loperamide. No side effects were encountered. It is concluded that loperamide can be considered an alternative symptomatic treatment in some IBS patients whose main symptoms are painless diarrhoea or alternating bowel habits associated with abdominal pain.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3306904     DOI: 10.3109/00365528709091004

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  39 in total

1.  British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome.

Authors:  J Jones; J Boorman; P Cann; A Forbes; J Gomborone; K Heaton; P Hungin; D Kumar; G Libby; R Spiller; N Read; D Silk; P Whorwell
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

Review 2.  Centrally acting agents and visceral sensitivity.

Authors:  J Fioramonti; L Bueno
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 3.  Diagnosis and management of IBS.

Authors:  Sarah Khan; Lin Chang
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10       Impact factor: 46.802

4.  The treatment of irritable bowel syndrome.

Authors:  Brian E Lacy; Kirsten Weiser; Ryan De Lee
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

Review 5.  Current and emerging pharmacotherapeutic options for irritable bowel syndrome.

Authors:  Jose L Barboza; Nicholas J Talley; Baharak Moshiree
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

Review 6.  Treatment of irritable bowel syndrome: a review of randomised controlled trials.

Authors:  R Akehurst; E Kaltenthaler
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

Review 7.  Drug treatment options for irritable bowel syndrome: managing for success.

Authors:  R C Dunphy; G N Verne
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

8.  Treatment of Irritable Bowel Syndrome.

Authors:  Robin C. Spiller
Journal:  Curr Treat Options Gastroenterol       Date:  2003-08

9.  New and Emerging Treatment Options for Irritable Bowel Syndrome.

Authors:  Brian E Lacy; William D Chey; Anthony J Lembo
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-04

Review 10.  New approaches to the medical treatment of irritable bowel syndrome.

Authors:  Driss Berrada; Katia Canenguez; Tony Lembo
Journal:  Curr Gastroenterol Rep       Date:  2003-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.